In recent years, biotechnology and industry have shown accelerated development globally, and major developed countries and emerging economies have deployed the development of bio-industry as one of the key areas to gain competitive advantage in the future science and technology economy. China has been promoting biotechnology R&D and industrial development for more than 30 years. Since the 11th Five-Year Plan, the State Council has approved and issued the "Policies for Accelerating the Development of Biotechnology Industry" and the "11th Five-Year Plan for the Development of Biotechnology Industry", and vigorously promoted biotechnology R&D and industrialization of innovative achievements. Utilization of foreign capital and international cooperation has made positive progress, the output value of the bio-industry is growing at an average annual rate of 22.9%, and the total output value realized in 2011 was about 2 trillion yuan, and the industries of biomedicine, bio-agriculture, bio-manufacturing and bio-energy have begun to take shape, with a number of large-scale enterprises with an annual sales volume of more than 10 billion yuan and large varieties with an annual sales volume of more than 1 billion yuan. China has initially established a certain foundation in biotechnology research and development, industry cultivation and market application. At present, China is facing increasingly serious challenges such as population aging, food safety and security, shortage of energy and resources, and deterioration of the ecological environment, etc. In order to safeguard the health of the population, food security and promote energy saving and emission reduction, it is necessary to accelerate the development, cultivation and popularization of new types of medicines, new varieties of crops, green planting technologies, biofuels and bioelectricity generation, bioenvironmental protection technologies, and biobased products. At the same time, it should be soberly seen that China's bio-industry still exists such outstanding problems as unsound industry management mechanism, imperfect market access policies and regulations, poor combination of scientific research and industry, lack of leading enterprises with core competitiveness and innovative and energetic small enterprises, etc., and will face increasingly fierce international competition in the process of development, and it is necessary to take forceful measures to solve the outstanding problems and create favorable conditions for accelerating the development of bio-industry. Favorable conditions to accelerate the development of bio-industry .
The 21st century is the era of life sciences, biotechnology in health care, agriculture, environmental protection, light chemical industry, food and other important areas to improve human health and living environment, improve agriculture and animal husbandry and industrial production and quality have begun to play an increasingly important role. Biotechnology has become the focus of modern scientific and technological research and development. In developed countries, biotechnology has become a new economic growth point, and its growth rate is roughly in the range of 25-30%, which is about 8-10 times of the average growth of the whole economy. China's biomedicine has grown roughly 100 times in 15 years.
In the field of biotechnology, China has listed 10 major fields and 35 categories of key technologies, and is striving to cultivate more than 1,000 large-scale enterprises in order to realize the strategy of a strong bio-economy. In the future, China will focus on the development of emerging vaccines, small-molecule drugs, emerging traditional Chinese medicine, high-yield and high-quality crops, biopesticides, biopharmaceutical industry, bioenergy, and environmental biotechnology. Meanwhile, it will expand the biotechnology industry chain and develop biomaterials.
As of 2000, the output value of China's biotechnology industry has reached more than 20 billion yuan, and more than 20 biotechnology parks have been established in Beijing, Shanghai, Guangzhou and Shenzhen. There are about 500 enterprises involved in modern biotechnology, employing more than 50,000 people, including more than 300 enterprises involved in pharmaceutical biotechnology and more than 200 enterprises involved in agricultural biotechnology.
As of 2006, the annual output value of China's modern biotechnology industry had reached 60 billion yuan, and that of traditional biotechnology industry had reached more than 300 billion yuan.
In 2007, there were about 500 enterprises involved in modern biotechnology, with an annual output value of nearly one trillion yuan. Biotechnology Industry Development Plan: By 2015, China's bio-industry will form a distinctive industrial development capacity, significantly enhance its contribution to economic and social development, and occupy a favorable position in the global industrial competition pattern. By 2020, the bio-industry development into a pillar industry of the national economy. Specific objectives include:
More reasonable structural layout. Key areas of the bio-industry achieve comprehensive development, new business forms grow healthily, key regions achieve characteristic development and staggered development, and the industrial structure is optimized. Cultivate a number of leading enterprises with international competitiveness and small and medium-sized enterprises with innovative vitality, and form a number of industrial clusters and advantageous industrial chains with their own characteristics and international influence.
Innovation capacity has been significantly strengthened. An industrial technology innovation system with international advanced level has basically been formed, the proportion of R&D investment in sales of major enterprises has been significantly increased, the number of key core technology breakthroughs has increased significantly, the number of patents authorized abroad has increased significantly, and a number of innovative products with independent intellectual property rights have been widely applied.
The scale and quality of the industry will be greatly improved, and the average annual growth rate of the output value of the bio-industry will remain above 20% from 2013 to 2015. By 2015, the added value of the bio-industry will double the proportion of GDP compared with 2010, and the rate of industrial added value will increase significantly.
The development environment will be significantly improved. It will form a better management system for market access, price formation and market supervision of new biological products and technologies, establish a two-way incentive policy system for encouraging innovation on both the supply side and the demand side, and improve the service system for industry public **** services, biosafety protection and industrial statistics.
Social benefits are accelerating. Biotechnology and bioproducts have been widely used, and the role of the bio-industry in improving the health of the population, safeguarding food and energy security, promoting green growth, improving the ecological environment and increasing employment opportunities has been significantly enhanced. However, China's bio-industry is relatively decentralized, small in scale and weak in technical strength, and should make full use of the government and the market to regulate the allocation of two kinds of resources, and revitalize China's technology, equipment and facilities, talents and other aspects of the stock, so as to make the advantages of all aspects of the system effectively integrated.
Bio-industry, like other high-tech industries, will become an important engine to pull China's economic take-off in the future. However, relative to the potential and demand for rapid development of the industry, the lack of capital and financing difficulties have become the bottleneck faced by many biotechnology enterprises. The development of bio-industry urgently needs the intervention of venture capital. Many investors have begun to pay attention to this industry.
Unlike the traditional pharmaceutical industry, the biotechnology industry felt the severe winter brought by the financial tsunami within a month. The entire biotech industry also experienced the most brutal capital market crash in history. After this financial tsunami, the market capitalization of most biotech companies will return to its natural state, and investors will be more cautious, which may be a good thing for the industry. The industry is very much alive, it is constantly developing new products, it will always maintain its creativity, and it will become stronger as it twists and turns.
The average annual growth rate will exceed 20%
The State Council issued the "Biological Industry Development Plan", making it clear that by 2020, the development of the biological industry will become a pillar industry of the national economy and other goals.
"Planning" also proposed that the next three years, the average annual growth rate of bio-industry output value will remain at more than 20%, by 2015, the proportion of the value added of the bio-industry GDP will be doubled compared with 2010, the biopharmaceutical industry will form a number of annual output value of more than 10 billion yuan of enterprises.
Biopharmaceuticals are prioritized for inclusion in medical insurance
Biopharmaceutical industry, the future will be comprehensive to accelerate the innovation ability of biopharmaceutical enterprises and product quality management capabilities, to promote the 2013-2015 annual average growth rate of output value of the biopharmaceutical industry to reach more than 20% and promote a number of independent intellectual property rights of the new drug market and the formation of a number of annual output value of more than tens of billion dollars of enterprises, biotechnology drugs, chemical drugs and traditional Chinese medicine. Various types of drugs such as biotechnology drugs, chemical drugs and traditional Chinese medicines will be supported.
Biopharmaceuticals, biological vaccines, protein peptide drugs and blood products will be the focus of support, the Plan will optimize the approval process of biopharmaceuticals, and develop and improve the biological drugs into the product catalog of the relevant policies of the medical insurance. In addition, a number of major human diseases related to genetic resources library, strain library, cell library, strain library of biopharmaceutical industrialization of R & D platform will be led by the state to establish the future will also build the above antibody drugs, protein peptide drugs and new vaccines industrialization demonstration project.
For generic drugs, the future will focus on cardiovascular and cerebrovascular diseases, metabolic diseases, malignant tumors, immune diseases, infectious diseases, neurological and psychiatric diseases to accelerate the innovation and industrialization of chemical drugs, which will focus on the promotion of slow-release, targeted, long-lasting, and other new preparations for research and development. In this regard, the state will improve the future price formation mechanism of chemical drugs and drug bidding mechanism, the implementation of raw and auxiliary materials for the registration of drugs for the record management system as well as the establishment of drug reference preparation selection guidelines catalog.
In addition, biomedical equipment innovation is also the focus of future support. The Plan indicates that by 2015 the annual output value of the biomedical engineering industry will reach 400 billion yuan, of which priority will be given to the development of high-performance medical imaging, radiation therapy, in vivo testing, in vitro diagnostics and other medical equipment development.
Segmented industries are supported
In addition to biomedicine and biomedical equipment, the "Plan" of bio-agriculture, bio-manufacturing, bio-energy and bio-environmental protection industry in the future development of clear support measures.
In support of the large-scale development of the bio-manufacturing industry, the Plan said it will promote the large-scale development and application of bio-based products, especially non-food bio-alcohols, organic acids and bio-olefins. In the future, a certification system for bio-based products will be established, and market incentive policies for the consumption of bio-based products and a rationing system for agricultural raw materials to the industrial sector will be formulated. In addition, green process products will be subsidized, and it is expected that the scale of the bio-manufacturing industry will reach 750 billion yuan by 2015.
In bio-agriculture, the industrial output value is expected to reach 300 billion yuan by 2015, and in particular a number of leading enterprises will be nurtured through support for enterprises to establish long-term and stable seed development partnerships with advantageous scientific and educational units.
In terms of bio-energy and bio-environmental protection, the total annual utilization of bio-energy will exceed 50 million tons of standard coal by 2015, and the output value of related industries will reach 150 billion yuan, especially in the future, the market access mechanism and price formation mechanism will be established in favor of ethanol gasoline and biodiesel. The next three years, biological environmental protection industry output value annual growth rate will be more than 15%, to 2015 annual output value will reach 150 billion yuan, which is used for soil and water restoration of various types of special enzyme preparations and microbial fungicide products will be the focus of support.